Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: A pilot study

Journal of Psychopharmacology

Volumn 24, Issue 3, 2010, Pages 333-339

  Bellino, S ^a   Paradiso, E ^a   Bozzatello, P ^a   Bogetto, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Adverse effects; Antidepressants; Borderline personality disorder; Duloxetine; Somatic symptoms

Indexed keywords

DULOXETINE; ADRENERGIC RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ADULT; ANGER; ARTICLE; BORDERLINE STATE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; IMPULSIVENESS; INSOMNIA; MALE; MOOD DISORDER; NAUSEA; OPEN STUDY; OUTPATIENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HEADACHE; HOSPITALIZATION; MIDDLE AGED; STATISTICS;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; BORDERLINE PERSONALITY DISORDER; FEMALE; HEADACHE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NAUSEA; PILOT PROJECTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; THIOPHENES;

EID: 77953063303     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108095715     Document Type: Article

References (59)

1. Allgulander, C, Hartford, J, Russell, J, Ball, S, Erickson, J, Raskin, J, et al (2007) Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 23: 1245-1252. (Pubitemid 46998433)
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, fourth ed. Text Revision (DSMIV-TR). Washington, DC: American. Psychiatric Association.
3. American Psychiatric Association (2001) Practice Guidelines for the Treatment of Patients with. Borderline Personality Disorder. Arlington, VA: American Psychiatric Association.
4. Arnold, LM (2007) Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2: 63-74.
5. Arnold, LM, Rosen, A, Pritchett, YL, D'Souza, DN, Goldstein, DJ, Iyengar, S, et al. (2005) A randomized, double-blind, placebo controlled trial of duloxetine in the treatment of women with fibromyalgia with or wiyhout major depressive disorder. Pain 119: 5-15.
6. Arnold, LM, Pritchett, YL, D'Souza, DN, Kajdasz, DK, Iyengar, S, Wernicke, JF (2007) Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 16: 1145-1156. (Pubitemid 47587341)
7. Arntz, A, Van. den Hoorn, M, Cornelis, J, Verheul, R, van den Bosch, WM, de Bie, AJ (2003) Reliability and validity of the borderline personality disorder severity index. J Personal Disord 17: 45-59. (Pubitemid 36343239)
8. Brannan, SK, Mallinckrodt, CH, Brown, EB, Wohlreich, MM, Watkin, JG, Schatzberg, AF (2005) Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39: 43-53 (Pubitemid 39422285)
9. Brecht, S, Courtecuisse, C, Debieuvre, C, Croenlein, J, Desaiah, D, Raskin, J, et al. (2007) Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 68: 1707-1716. (Pubitemid 350247500)
10. Coccaro, EF, Kavoussi, RJ (1997) Fluoxetine and impulsive aggressive behaviour in personality disordered subjects. Arch Gen Psychiatry 54: 1081-1088.
11. Coccaro, EF, Lee, R, McCloskey, M (2003) Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression. CNS Spectr 8: 731-736. (Pubitemid 38405554)
12. Cornelius, JR, Soloff, PH, Perel, JM, Ulrich, RF (1990) Fluoxetine trial in borderline personality disorder. Psychopharmacol. Bull 26: 151-154. (Pubitemid 20322264)
13. Cornelius, JR, Soloff, PH, Perel, JM, Ulrich, RF (1991) A preliminary trial of fluoxetine in refractary borderline patients. J Clin Psychopharmacol 11: 116-120.
14. Davidson, J, Allgulander, C, Pollack, MH, Hartford, J, Erickson, JS, Russell, JM, et al. (2008) Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Hum Psychopharmacol. [published online: 14 May 2008].
15. Derogatis, LR, Lipman, RS, Covi, L (1973) SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull 9: 13-28.
16. Detke, MJ, Lu, Y, Goldstein, DJ, Hayes, JR, Demitrack, MA (2002) Duloxetine, 60 mg once daily, for major depressive disorder. A randomised double-blind placebo-controlled trial. J Clin Psychiatry 63: 308-315. (Pubitemid 34456358)
17. Dunner, DL, Wilson, M, Fava, M, Kornstein, S, Munoz, R, O'Reardon, J, et al. (2008) Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety 25: E1-E8.
18. Endicott, J, Russell, JM, Raskin, J, Detke, MJ, Erickson, J, Ball, SG, et al. (2007) Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. J Clin Psychiatry 68: 518-524. (Pubitemid 46663033)
19. First, MB, Gibbon, M, Spitzer, RL, Williams, JBW (1997a) Structured Clinical Interview for DSM-IV disorders (SCID). Arlington, VA: American Psychiatric Press.
20. First, MB, Gibbon, M, Spitzer, RL, Williams, JBW (1997b) Structured Clinical Interview for DSM-IV disorders Axis II (SCID-II). Arlington, VA: American Psychiatric Press.
21. Goldman, HH, Skodol, AE, Lave, TR (1992) Revising Axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 149: 1148-1156.
22. Goldstein, DJ, Lu, Y, Detke, MJ, Hudson, J, Iyengar, S, Demitrack, MA (2004) Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45: 17-28. (Pubitemid 38082504)
23. Gollan, JK, Lee, R, Coccaro, EF (2005) Developmental psychopathology and neurobiology of aggression. Dev Psychopathol 17: 1151-1171.
24. Guy, W (1976a) Clinical global impression (C.G.I.). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health, Rockville, MD, 218-222.
25. Guy, W (1976b) Dosage Record and Treatment Emergent Symptoms scale (DOTES), In: ECDEU assessment manual for psychopharmacology - revised. DHEW Publication No. ADM 76-338. Rockville, MD; US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 223-244.
26. Hamilton, M (1959) The assessment of anxiety states by rating. Br J Med. Psychol 32: 50-55.
27. Hamilton, M (1960) A. rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
28. Hartford, J, Komstein, S, Liebowitz, M, Pigott, T, Russell, J, Detke, M, et al. (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: result from a placebo and active-controlled trial. Int Clin Psychopharmacol 22: 167-174. (Pubitemid 46559873)
29. Hirshfeld, RMA, Mallinckrodt, C, Lee, TC, Detke, MJ (2005) Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 21: 170-177. (Pubitemid 41170386)
30. Hudson, JI, Perahia, DG, Gilaberte, I, Wang, F, Watkin, JG, Detke, MJ (2007) Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 7: 43.
31. Kavoussi, RJ, Liu, J, Coccaro, EF (1.994) An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 55: 137-141.
32. Koponen, H, Allgulander. C, Erickson, J, Dunayevich, E, Pritchett, Y, Detke, MJ, et al. (2007) Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim. Care Companion J Clin Psychiatry 9: 100-107. (Pubitemid 46607463)
33. Lyons-Ruth, K, Holmes, BM, Sasvari-Szekely, M, Ronai, Z, Nemoda, Z, Pauls, D (2007) Serotonin transporter polymorphism and borderline or antisocial traits among low-income young adults. Psychiatr Genet 17: 339-343. (Pubitemid 351339816)
34. Markovitz, P (1990) Fluoxetine treatment of self-injurious behavior in mentally retarded patients. J Clin Psychopharmacol 10: 299-300. (Pubitemid 20319186)
35. Markovitz, P (1995) Pharmacotherapy of impulsivity, aggression, and related disorders. In: Hollander, E, Stein, DJ (eds), Impulsivity and Aggression. New York, NY: John Wiley & Sons, pp. 263-287.
36. Markovitz, P, Wagner, S (1995) Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 31: 773-777. (Pubitemid 26091746)
37. Nemeroff, CB, Schatzberg, AF, Goldstein, DJ, Detke, MJ, Mallinckrodt, C, Lu, Y, et al. (2002) Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 36: 106-132.
38. Ni, X, Chan, K, Bulgin, N, Sicard, T, Bismil, R, McMain, S, et al. (2006) Association between serotonin transporter gene and borderline personality disorder. J Psychiatr Res 40: 448-453. (Pubitemid 43816590)
39. Ni, X, Sicard, T, Bulgin, N, Bismil, R, Chan, K, McMain, S, et al. (2007) Monoamine oxidase a gene is associated with borderline personality disorder. Psychiatr Genet 17: 153-157. (Pubitemid 46716207)
40. Nicolini, H, Bakish, D, Duenas, H, Spann, M, Erickson, J, Hallberg, C, et al. (2008) Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med. 19: 1-10.
41. Norden, MJ (1.989) Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 13: 885-893.
42. Oldham, JM (2005) Guideline Watch: Practice Guideline for the Treatment of Patients with Borderline Personality Disorder. Arlington, VA: American Psychiatric Association.
43. Oquendo, MA, Mann, JJ (2000) The biology of impulsivity and suicidally. Psychiatr Clin North Am 23: 11-25.
44. Paris, J, Zweig-Frank, H, Kin, NM, Schwartz, G, Steiger, H, Nair, NPV (2004) Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls. Psychiatry Res 121: 239-252. (Pubitemid 37522177)
45. Pascual, JC, Soler, J, Baiget, M, Cortés, A, Menoyo, A, Barrachina, J, et al. (2007) Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). Actas Esp Psiquiatr 35: 382-386.
46. Perahia, DG, Kajdasz, DK, Royer, MG, Walker, DJ, Raskin, J (2006) Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. Int Clin Psychopharmacol 21: 285-295.
47. Raskin, J, Wiltse, CG, Dinkel, JJ, Walker, DJ, Desaiah, D, Katona, C (2008) Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 28: 32-38.
48. Rinne, T, de Kloet, ER, Wouters, L, Goekoop, JG, DeRijk, RH, van den Brink, W (2002) Hyperresponsiveness of hypothalamicpituitary-adrenal axis to combined dexamethasone/corticotropinreleasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biol Psychiatry 52: 1102-1112. (Pubitemid 35379967)
49. Rooks, DS (2007) Fibromyalgia treatment update. Curr Opin Rheumatol 19: 111-117.
50. Russell, JM, Weisberg, R, Fava, M, Hartford, JT, Erickson, JS, D'Souza, DN (2007) Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety [published online: 22 June 2007].
51. Russell, IJ, Mease, PJ, Smith, TR, Kajdasz, DK, Wohlreich, MM, Detke, MJ, et al. (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136: 432-444.
52. Rynn, M, Russell, J, Erickson, J, Detke, MJ, Ball, S, Dinkel, J, et al. (2008) Efficacy and safety of duloxetine in the treatment of gener alized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25: 182-189. (Pubitemid 351499896)
53. Salzman, C, Wolfson, AN, Schatzberg, A, Looper, J, Henke, R, Albanese, M, et al (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23-29.
54. Sansone, RA, Pole, M, Dakroub, H, Butler, M (2006) Childhood trauma, borderline personality symptomatology, and psychophysiological and pain disorders in adulthood. Psychosomatics 47: 158-162. (Pubitemid 43346965)
55. Soloff, PH, Price, JC, Meltzer, CC, Fabio, A, Frank, GK, Kaye, WH (2007) 5HT2A receptor binding is increased in borderline personality disorder. Biol Psychiatry 62: 580-587. (Pubitemid 47314369)
56. Teicher, MH, Glod, CA, Cole, JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147: 207-210. (Pubitemid 20060476)
57. Van den Eynde, F, Senturk, V, Naudts, K, Vogels, C, Bernagie, K, Thas, O, et al. (2008) Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 28: 147-155. (Pubitemid 351417119)
58. Ventura, J, Green, M, Shaner, A, Liberman, R (1993) Training and quality assurance with the brief psychiatry rating scale: "the drift busters". Int J Methods Psychiatr Res 3: 221-244.
59. Wohlreich, MM, Wiltse, CG, Desaiah, D, Ye, W, Robinson, RL, Kroenke, K, et al. (2007) Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study. Prim. Care Companion J Clin Psychiatry 9: 271-279. (Pubitemid 47219583)